NMD4C Launch Educational Platform LEARNMD
NMD4C is thrilled to introduce LEARNMD, an online educational platform offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. This platform is designed to provide Canadian clinicians and researchers at every career stage with high-quality training and educational resources tailored to their specific neuromuscular interests.
LEARNMD offers a self-directed personalized learning experience tailored to learners’ specific interests, covering neuromuscular disorders, translational and clinical research, therapies, and management strategies. The platform hosts hundreds of educational resources, including recordings of our monthly accredited series and others from organizations we have partnered with. LEARNMD will be regularly updated with new content, ensuring access to the latest research developments and clinical updates.
If you are a Canadian clinician, researcher, and member of the NMD4C we invite you to create a LEARNMD user profile for free. Sign up for the platform here!
We are seeking to build the library of content available in LEARNMD – If you have delivered or attended any neuromuscular-related talks that you think should be included, please reach out to let us know! For any questions about the LEARNMD platform, please contact education and curriculum coordinator Victoria Larocca at
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.